Pregabalin Market Size, Share & Industry Analysis, By Dosage form (Oral [Capsules, Solution, Tablet, and Others] and Parenteral), By Application (Neuropathic Pain, Fibromyalgia, Epilepsy, and Others), By Product Type (Branded and Generic), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2026-2034

The pregabalin market is rising rapidly. Pregabalin is a drug used to treat neuropathic pain, which may occur in the arms, fingers, and feet if an individual has diabetes and postherpetic neuralgia. Pregabalin is also used to treat spinal cord injury and for the treatment of fibromyalgia. By combining pregabalin with other medicines, it is also used to treat various types of seizures in children and adults.

The rise in the prevalence of epilepsy also boosts the growth of the market. Epilepsy is a chronic neurological disorder that often requires continuous treatment. Additionally, the rise in cases of diabetes also drives the growth of the market. 

• For instance, according to the data published by the World Health Organization (WHO), in February 2024, approximately 50 million people in the world have epilepsy, and about 80% of these patients are from the lower- or middle-class income countries.

Pregabalin Market Driver

High Prevalence of Epilepsy to Drive Market Growth

The main driving factor of the market is the increase in the prevalence and awareness of the disease of epilepsy. Epilepsy is one of the most common diseases in neurology. Additionally, pregabalin is also used for pain relief and anxiety management even in patients who do not suffer from epilepsy. 

• For instance, according to the data published by Cochrane, in March 2022, about 1% of people in the U.K. are affected by epilepsy, a common chronic neurological disease that causes seizures in approximately 1 out of 400 patients.

Prevalence of Epilepsy in Some Asian Countries (Per 1000), 2023

According to the data published by Acta Epileptologica in October 2023, the prevalence of epilepsy in Asia is estimated to be 23 million individuals. Some of the countries with the highest prevalence rates of epilepsy include India and China.

Pregabalin Market Restraint

Strict Regulatory Policies Limit Market Growth

Stringent government or regulatory policies due to the chances of abuse of pregabalin significantly restrict the market growth. Additionally, other factors such as adverse drug effects of the drug, which include severe allergic reactions, and the availability of other alternative treatments decrease the growth of the global market.

• For Instance, according to the data published in The Indian Practitioner, in February 2025, the Government of India announced plans to exert strict controls on pregabalin to restrict its abuse. Authorities are planning the introduction of pregabalin and its various formulations under Schedule H1.

Pregabalin Market Opportunity

High Demand to Boost Introduction of New Generics & Conduct of Clinical Trials

A consistent rise in the demand for pregabalin may boost the growth of the market in the future. Other factors such as ongoing research and development initiatives, increase the scope for the approval of new indications for pregabalin.

• For instance, according to the latest research published in Healio in January 2025, duloxetine, milnacipran, and pregabalin may lead to the improvement of pain associated with fibromyalgia for one in 10 patients.

Key Insights

The report covers the following key insights:

• Prevalence of Key Diseases, By Key Countries, 2024
• New Product Launches/ Approvals, By Key Players
• Pipeline Analysis, By Key Players
• Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• Impact of COVID-19 on the Market

 Segmentation

Analysis by Dosage Form

By dosage form, the market is divided into oral [capsules, solution, tablet, and others] and parenteral.

The oral dosage form held a significant share in the global market. The oral dosage form can be further sub-segmented into capsules, tablets, solutions, and others. As this is one of the most convenient forms, this is also one of the most common dosage forms used. Furthermore, in a number of cases, the medication of pregabalin is given through the oral route.

• For instance, in March 2025, Strides Pharma Science Limited announced that it had received the U.S. FDA approval for pregabalin capsules in the strengths of 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg.

Analysis by Application

By application, the market is divided into neuropathic pain, fibromyalgia, epilepsy, and others.

The epilepsy segment accounted for a major proportion of the global market. Epilepsy was one of the very foremost clinical indications for which this medication was approved. Usage of pregabalin for epilepsy is approved for both pediatric and adult patients.

• For instance, according to the data published by the U.S. Centers for Disease Control and Prevention, in May 2024, an estimated 2.9 million adults (ages 18 and older) reported having an active form of epilepsy.

Analysis by Product Type

By product type, the market is divided into branded and generic.

The generic formulations of the drug account for a prominent portion of the global market. Initially, pregabalin was a patented drug which manufactured by Pfizer, Inc., and Lyrica was their brand name. After the expiry of the company’s patents, the generic formulation of pregabalin was available in the market at a very competitive price. The advantage of lower pricing allowed greater access for a diverse group of patients to this critical drug. 

• In July 2019, the U.S. FDA granted approvals for the multiple clinical indications of pregabalin for the first group of generics. These approvals were granted to a number of pharmaceutical companies, including Amneal Pharmaceuticals, Dr. Reddy’s Laboratories, and others.

Analysis by Distribution Channel

By distribution channel, the market is divided into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies.

Online pharmacies are projected to grow at the highest CAGR across the forecast period. While pregabalin is a highly regulated drug, the ease and convenience extended to the users of online pharmacies is expected to contribute to the segmental growth. Furthermore, recent segmental trends such as the launches of online pharmacies by prominent companies are further expected to result in the segment’s positive growth trajectory.

• In August 2020, Amazon announced the launch of an online pharmacy in India. Amazon’s online pharmacy in India offers pregabalin medications for online purchase. 

Regional Analysis 

By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America.

Request for Customization   to gain extensive market insights.

North America is expected to account for a dominant proportion of the global market. North America has a developed healthcare infrastructure, a high prevalence of epilepsy, and significant R&D investments in pharmaceuticals. These factors drive the growth of the market in this region. Additionally, the presence of key industry players and favorable regulatory policies supports the market growth in this region. 

• For instance, according to the data published by the Public Health Agency of Canada in May 2024, in the fiscal years of 2021 and 2022, an estimated 1 out of 100 Canadians suffered from epilepsy.

Europe is also the leading region in terms of the global pregabalin market. As Europe has a high prevalence of several chronic diseases, such as epilepsy and neuropathy, the demand for pregabalin in the market is expected to be strong in the region. 

• In July 2024, Adalvo announced the launch of the first and only pregabalin extended-release (ER) tablets in the European region. The products were launched in the two European markets of Germany and Spain. 

The Asia Pacific region is expected to grow at the highest growth rate owing to a strong patient burden for chronic diseases, including epilepsy, an increasingly improving healthcare infrastructure, and the presence of prominent companies in the region.

Key Players Covered

The global pregabalin market reflects a fragmented competitive structure with the presence of several companies. The report includes the profiles of the following key players:

• Pfizer Inc. (U.S.)
• Torrent Pharmaceuticals Ltd (India)
• Lupin (India)
• Zydus Group (India)
• Cipla (India)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Amneal Pharmaceuticals LLC. (U.S.)
• Aurobindo Pharma Limited. (India)
• GLENMARK PHARMACEUTICALS LTD. (India)

Key Industry Developments

• In March 2025, CNX Therapeutics Limited announced the launch of MISABRI PR (Pregabalin) prolonged-release tablets, a formulation of pregabalin that can be taken once a day. Adults can take this medication for peripheral and central neuropathic pain.
• In May 2024, Indoco Remedies announced that it had received a U.S. FDA approval for an Abbreviated New Drug Application (ANDA) for Pregabalin capsules. This approval was for the dosages of 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, and 300mg.